Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mushboost: Agaricus Bisporus Powder for Influenza Vaccine Response
NCT06041867Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Sep 2023
- Primary completion
- Dec 2023
- Countries
- 1
01
Overview
Randomised, double-blind trial (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Vaccine specific antibody titer at 4 weeks. Started Sep 2023; status: completed.
Beyond the preview
Go deeper on NCT06041867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041867.